These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 24347428

  • 1. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome.
    Tosi F, Di Sarra D, Bonin C, Zambotti F, Dall'Alda M, Fiers T, Kaufman JM, Donati M, Franchi M, Zanolin ME, Bonora E, Moghetti P.
    Eur J Endocrinol; 2014 Mar; 170(3):401-9. PubMed ID: 24347428
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome?
    Sari U, Kaygusuz I, Kafali H.
    Gynecol Obstet Invest; 2014 Mar; 78(3):173-8. PubMed ID: 25011417
    [Abstract] [Full Text] [Related]

  • 4. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome.
    Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, Muggeo M, Moghetti P.
    Eur J Endocrinol; 2009 Nov; 161(5):737-45. PubMed ID: 19713424
    [Abstract] [Full Text] [Related]

  • 5. Elevated plasma pentraxin-3 in polycystic ovary syndrome is associated with hyperandrogenism: a case-control study.
    Jin C, Zou K, Xu Y, Yang H, Pan J.
    BMC Endocr Disord; 2021 Dec 03; 21(1):240. PubMed ID: 34856980
    [Abstract] [Full Text] [Related]

  • 6. Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS).
    Wyskida K, Franik G, Pohl N, Markuszewski L, Owczarek A, Madej P, Chudek J, Olszanecka-Glinianowicz M.
    Scand J Clin Lab Invest; 2019 Oct 03; 79(6):419-423. PubMed ID: 31282210
    [Abstract] [Full Text] [Related]

  • 7. Elevated ovarian pentraxin 3 in polycystic ovary syndrome.
    Pan J, Zhou C, Zhou Z, Yang Z, Dai T, Huang H, Jin L.
    J Assist Reprod Genet; 2021 May 03; 38(5):1231-1237. PubMed ID: 33594624
    [Abstract] [Full Text] [Related]

  • 8. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F.
    Gynecol Endocrinol; 2014 Nov 03; 30(11):781-4. PubMed ID: 25137507
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
    Moradi S, Mollabashi M, Kerman SR.
    Gynecol Endocrinol; 2011 Jul 03; 27(7):480-5. PubMed ID: 20836727
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2007 Jun 03; 92(6):2066-73. PubMed ID: 17356050
    [Abstract] [Full Text] [Related]

  • 16. [Research progress on the role of pentraxin 3 in polycystic ovary syndrome].
    Wu W, Xu J.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 Oct 25; 49(5):637-643. PubMed ID: 33210493
    [Abstract] [Full Text] [Related]

  • 17. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar 25; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 18. Polycystic ovary syndrome is associated with increased osteopontin levels.
    Saklamaz A, Calan M, Yilmaz O, Kume T, Temur M, Yildiz N, Kasap E, Genc M, Sarer Yurekli B, Unal Kocabas G.
    Eur J Endocrinol; 2016 Apr 25; 174(4):415-23. PubMed ID: 26701868
    [Abstract] [Full Text] [Related]

  • 19. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism.
    Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, Zambotti F, Dall'Alda M, Caruso B, Zanolin ME, Bonora E, Moghetti P.
    J Clin Endocrinol Metab; 2013 Jun 25; 98(6):2581-8. PubMed ID: 23596136
    [Abstract] [Full Text] [Related]

  • 20. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome.
    Cakal E, Ustun Y, Engin-Ustun Y, Ozkaya M, Kilinç M.
    Gynecol Endocrinol; 2011 Jul 25; 27(7):491-5. PubMed ID: 20626239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.